CATX halted on Oct 23 2026 at $2.28
CATX+0.9%on Fri Oct 23 2026
Perspective Therapeutics, Inc. was up 0.9% on the day at $2.28, ranked #642 on — its usual five-minute volume, when TapeRank recorded this trading halt at 08:23 ET during the pre-market session when it was halted. TapeRank recorded 3 events for CATX that day, between 08:23 and 11:13 ET, and each is in the timeline below.
THE DAY ON THE LIST · 3 EVENTS
- 08:23 ETHALT · PRE-MARKET
HALTED AT $2.28 · ▲ 0.9% ON THE DAY · — 5M RVOL · RANK #642
No verdict was committed for this event.
THE ROW AND SESSION LEVELS AT 08:23 ET
LAST2.28DAY▲ 0.9%5 MIN· 0.00%5M RVOL—5M $VOL—FLOAT*114.2MRANK#642SESSIONPRE-MARKETVWAP2.28HOD2.29LOD2.28OR HIGH—OR LOW—PREV CLOSE2.26PM HIGH2.29PM LOW2.28GAP▲ 0.88% (indicated)* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
- 11:13 ETUNEXPLAINED MOVE · REGULAR
$1.83 · ▼ 19.0% ON THE DAY · 16.1× 5M RVOL · RANK #8
UNEXPLAINEDCONFIDENCE4/5CATX is down 15.3% on the day and another 8.15% in five minutes despite the supplied news describing interim Phase 1/2a data without reporting the actual results. The material provides no clearly negative catalyst, so the immediate decline is being driven by order flow rather than an explained event.
WHYA 15.3% selloff and abrupt 8.15% five-minute drop are large relative to the provided announcement, which identifies interim data but gives no adverse efficacy or safety detail.ANALYZED 11:12 ET · <1 MIN AGO · OPENAI/GPT-5.6-LUNATHE ROW AND SESSION LEVELS AT 11:13 ET
LAST1.83DAY▼ 19.0%5 MIN▼ 10.73%5M RVOL16.1×5M $VOL$383KFLOAT*114.2MRANK#8SESSIONREGULARVWAP2.09HOD2.40LOD1.90OR HIGH—OR LOW—PREV CLOSE2.26PM HIGH2.29PM LOW2.28GAP▲ 6.19%* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
- 11:13 ETMOVER · REGULAR
$1.80 · ▼ 20.3% ON THE DAY · 21.8× 5M RVOL · RANK #5
The same verdict as at 11:13 ET.
THE ROW AND SESSION LEVELS AT 11:13 ET
LAST1.80DAY▼ 20.3%5 MIN▼ 12.19%5M RVOL21.8×5M $VOL$511KFLOAT*114.2MRANK#5SESSIONREGULARVWAP2.08HOD2.40LOD1.83OR HIGH—OR LOW—PREV CLOSE2.26PM HIGH2.29PM LOW2.28GAP▲ 6.19%* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
NO VERDICT MEANS THE MODEL HAD NOT REACHED THE NAME BEFORE THE EVENT WAS FINALIZED, OR ITS ANSWER HEDGED AND WAS WITHHELD. NOTHING WAS FILLED IN AFTERWARDS.
THE SESSION
- 08:12 ETHalted (T1); resumed 11:05 ET, after 173 minutes
- 11:05 ETOpened at $2.40, +6.2% on the previous close of $2.26
- 11:05 ETRegular-session high, $2.40
- 15:16 ETRegular-session low, $1.58
- 15:59 ETLast trade of the regular session, $1.60, -29.2% on the previous close of $2.26
- Volume: 5.4M shares in regular hours, 2K before the open
CATX opened at $2.40 after a 173-minute halt and briefly held that level before falling to $1.58 by 15:16, then ended the regular session at $1.60, down 29.2% from the previous close. TapeRank tied the move to no clear explanation: the 10:54 ET news described interim Phase 1/2a data from Perspective Therapeutics’ study, but reported no actual results or adverse efficacy or safety details, while the SEC filing was an 8-K covering other events and exhibits. The stock’s largest recorded move was a 20.3% decline at 11:13 ET.
WRITTEN FRI OCT 23 2026 16:00 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE
FILINGS AND NEWS · 24H BEFORE THE MOVE
- 10:54 ETPerspective Therapeutics Announces Interim Data From Its Current Phase 1/2a Clinical Study Of [212Pb]VMT-α-NET In Patients With Unresectable Or Metastatic Somatostatin Receptor Type 2 Expressing Neuroendocrine Tumors At ESMO Congress 2026Benzinga
- 10:52 ET8-K — Other Events; Financial Statements and ExhibitsSEC 8-K
On the tape right now
WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY
Open the full list